Cannabis could hold the key to ending multiple sclerosis misery

Apr 02, 2007

Researchers investigating the role of cannabinoids - chemical substances contained within cannabis – in the treatment of multiple sclerosis (MS), have found they could significantly enhance therapy, not only by reducing nerve damage and erratic nerve impulses, but perhaps even by hindering development of the condition.

The findings, published online today (1 April, 2007) in Nature Medicine demonstrates for the first time how cannabis might actually slow down the progression of MS and could have major implications for the estimated 2.5 million sufferers worldwide.

Using a mouse model, a team of UK, European, Japanese and US scientists, led by David Baker, Professor of Neuroimmunology at Queen Mary, University of London, found that doses of the active component within cannabis, tetrahydrocannabinol (THC) could significantly inhibit the development and severity of MS.

Cannabis works because it stimulates molecules known as cannabinoid receptors within the body. The group had previously reported that THC could alleviate disease symptoms, and also save nerves from the damaging effects of the disease - thus potentially, via the cannabinoid receptor CB1, slowing down the development of progressive disability. They had not previously examined the influence of cannabinoids on immune aspects of the disease.

Now their most recent study has successfully separated the roles of cannabinoid receptors CB1 and CB2 on neurons and T cells, and investigated their effect in controlling central nervous system autoimmunity. It showed that CB1 receptor expression by nerves in the brain, but not T cells, could suppress the development of an experimental MS-like disease, by stimulating the release of anti-inflammatory molecules, whilst in contrast direct stimulation of CB2 receptors by T cells was also able to control inflammation associated with the condition. This suggests that cannabis-like drugs may have the potential to block the autoimmune response which drives disease development.

Professor David Baker said: “Whilst targeting CB1 receptors for therapy runs the risk of causing the unwanted “high” to achieve these effects, we can get the same result by targeting CB2 receptors, which avoids these risks. Therefore, we can start to think about using new drugs that harness the potential medical benefits that cannabis has to offer but move away from the issues over the legality and recreational use of the plant product”.

Source: Queen Mary, University of London

Explore further: Medicinal GPS: DNA nanotechnology-based approach allows injected drugs to find tumor sites

add to favorites email to friend print save as pdf

Related Stories

Mobile use bad for school test scores: Japan study

1 hour ago

Children who spend more than four hours a day on their mobile phone perform significantly worse on school tests than those who are limited to just 30 minutes, a Japanese government survey has found.

Amazon could be ESPN of video games in Twitch deal

2 hours ago

Amazon is hoping to become the ESPN of video games. The e-commerce giant is buying streaming platform Twitch Interactive for $970 million in cash as it seeks to take part in video gaming's growth as an onlin ...

A look at earthquake's impact on California region

11 hours ago

A strong earthquake rattled a swath of Northern California's wine country in the early hours of Sunday morning, unleashing most of its damage on the city of Napa in the heart of the vineyard-studded region.

Recommended for you

How Alzheimer's peptides shut down cellular powerhouses

11 hours ago

The failing in the work of nerve cells: An international team of researchers led by Prof. Dr. Chris Meisinger from the Institute of Biochemistry and Molecular Biology of the University of Freiburg has discovered ...

User comments : 0